Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents

Current Oncology

Volumn 19, Issue 4, 2012, Pages 202-208

  Larochelle, P ^a   Kollmannsberger, C ^b   Feldman, R D ^c   Schiffrin, E L ^d   Poirier, L ^e   Patenaude, F ^d   Ruether, D ^f   Myers, M ^g   Bjarnason, G ^g  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f TOM BAKER CANCER CENTRE   (Canada)

^g SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Hypertension; Metastatic renal cell carcinoma; Vascular endothelial growth factor inhibitors

Indexed keywords

ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AXITINIB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LINIFANIB; NITRIC OXIDE; PAZOPANIB; SORAFENIB; SUNITINIB; THIAZIDE DIURETIC AGENT; VASCULOTROPIN; VERAPAMIL;

ADVANCED CANCER; ANTIHYPERTENSIVE THERAPY; ANTINEOPLASTIC ACTIVITY; AORTA ANEURYSM; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BRAIN HEMORRHAGE; CANCER SURVIVAL; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL ASSESSMENT; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG METABOLISM; DRUG SAFETY; DRUG TREATMENT FAILURE; ENZYME INHIBITION; ENZYME RELEASE; ENZYME SYNTHESIS; EXERCISE; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY METASTASIS; LIFESTYLE MODIFICATION; MEDICAL SPECIALIST; MULTIPLE CYCLE TREATMENT; PRACTICE GUIDELINE; PRESSORECEPTOR; PROCESS OPTIMIZATION; PROTEINURIA; RISK ASSESSMENT; SIDE EFFECT; SIGNAL TRANSDUCTION; SODIUM RESTRICTION; SOLID TUMOR; STROKE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 84865173286     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.972     Document Type: Article

References (32)

1. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
2. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009;48:9-17.
3. Maitland ML, Kasza KE, Karrison T, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009;15:6250-7.
4. Négrier S, Ravaud A. Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. Eur J Cancer Suppl 2007;5:12-19.
5. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26:5204-12.
6. Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance and management of blood pressure in patients receiving vascular endothelial growth factor signalling pathway inhibitors. J Natl Cancer Inst 2010;102:596-604.
7. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008;358:95-7.
8. Tolcher AW, Appleman LJ, Shapiro GI, et al. A phase 1 openlabel study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol 2011;67:751-64.
9. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103:763-73.
10. Rini BI, Schiller JH, Fruehauf JP, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011;17:3841-9.
11. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase iii trial. Lancet 2007;370:2103-11.
12. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: calgb 90206. J Clin Oncol 2008;26:5422-8.
13. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24.
14. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
15. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase 2 study. Lancet Oncol 2007;8:975-84.
16. Rini BI, Wilding G, Hudes G, et al. Phase 2 study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4462-8.
17. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
18. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase ii trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1280-9.
19. Tannir N, Wong Y, Kollmannsberger C, et al. Phase 2 study of ABT-869 in advanced renal cell carcinoma (rcc) after sunitinib failure: efficacy and safety results [abstract 5036]. J Clin Oncol 2009;27:. [Available online at: http://www.asco. org/ASCOv2/Meetings/Abstracts? &vmview=abst_detail_view &confID=65&abstractID=30462; cited May 27, 2012]
20. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase iii trial. J Clin Oncol 2010;28:1061-8.
21. United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program (ctep). Common Terminology Criteria for Adverse Events. Ver. 3.0. Bethesda, MD: ctep; 2006. [Available online at: http://ctep.cancer.gov/protocol development/electronic_applications/docs/ctcaev3.pdf; cited May 27, 2012]
22. Roodhart JM, Langenberg MH, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the vegf/vegfr pathway. Curr Clin Pharmacol 2008;3:132-43.
23. Kappers MH, van Esch JH, Sleijfer S, Danser AH, van den Meiracker AH. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. J Hypertens 2009;27:2297-309.
24. Padwal RS, Hemmelgarn BR, Khan NA, et al. on behalf of Canadian Hypertension Education Program. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1-blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2009;25:279-86.
25. Khan NA, Hemmelgarn B, Herman RJ, et al. on behalf of Canadian Hypertension Education Program. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy. Can J Cardiol 2009;25:287-98.
26. Campbell NR, Khan NA, Hill MD, et al. on behalf of the Canadian Hypertension Education Program. 2009 Canadian Hypertension Education Program recommendations: the scientific summary-an annual update. Can J Cardiol 2009;25:271-7.
27. Zarnke KB, Campbell NR, McAlister FA, Levine M on behalf of the Canadian Hypertension Recommendations Working Group. A novel process for updating recommendations for managing hypertension: rationale and methods [English and French]. Can J Cardiol 2000;16:1094-102.
28. McAlister FA. The Canadian Hypertension Education Program-a unique Canadian initiative. Can J Cardiol 2006;22:559-64.
29. Bamias A, Manios E, Karadimou A, et al. The use of 24-h ambulatory blood pressure monitoring (abpm) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer. Eur J Cancer 2011;47:1660-8.
30. Myers MG, Tobe SW, McKay DW, Bolli P, Hemmelgarn BR, McAlister FA on behalf of the Canadian Hypertension Education Program. New algorithm for the diagnosis of hypertension. Am J Hypertens 2005;18:1369-74.
31. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Kaczorowski J. Measurement of blood pressure in the office- recognizing the problem and proposing the solution. Hypertension 2010;55:195-200.
32. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007;1(suppl 2):S41-54.